Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- NB300-182 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#NB300-182, RRID:AB_10001711
- Product name
- Rabbit Polyclonal NMDAR2B Antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified. Specific for the ~180k NMDAR NR2B-subunit protein phosphorylated at Tyr1472 in Western blots. The antibody also labels proteins of ~65k and ~115k. Immunolabeling is completely blocked by blocked by either gamma-Ptase or by the phosphopeptide used as the antigen but not by the corresponding dephosphopeptide.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 0.1 ml
- Storage
- Store at -20C. Avoid freeze-thaw cycles.
Submitted references Increased NRG1-ErbB4 signaling in human symptomatic epilepsy.
Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking.
Zhu JM, Li KX, Cao SX, Chen XJ, Shen CJ, Zhang Y, Geng HY, Chen BQ, Lian H, Zhang JM, Li XM
Scientific reports 2017 Mar 10;7(1):141
Scientific reports 2017 Mar 10;7(1):141
Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking.
Hallett PJ, Spoelgen R, Hyman BT, Standaert DG, Dunah AW
The Journal of neuroscience : the official journal of the Society for Neuroscience 2006 Apr 26;26(17):4690-700
The Journal of neuroscience : the official journal of the Society for Neuroscience 2006 Apr 26;26(17):4690-700
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: NMDAR2B [p Tyr1472] Antibody [NB300-182] - Rat hippocampal lysate showing specific immunolabeling of the ~180 kDa NR2B subunit of the NMDAR phosphorylated at Tyr1472 in the first lane (-). Phosphospecificity is shown in the second lane (+) where immunolabeling is completely eliminated by lysate treatment with lambda phosphatase (400 units/100uL lysate for 30 min).
